United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

The size of the North America Self-monitoring Blood Glucose Market was valued at USD 8.10 Million in 2023 and is projected to reach USD 12.99 Million by 2032, with an expected CAGR of 6.98% during the forecast period. Self-monitoring blood glucose is a relevant tool for patients with diabetes. Its process includes the regular testing of blood sugar to gauge how the body reacts to food, medicine, or physical activity. It helps increase peoples' awareness of their own choices and helps them avoid some complications that may come as a result of diabetes. The North American SMBG market is driven by the increasing incidences of diabetes, especially Type 2. The size and risk profile of the population are critical factors in North America. The region suffers from a rather large population that is susceptible to developing the disease primarily because of obesity, sedentary lifestyles, and aging. With the growth in awareness of diabetes, and with preventive and controlling features forming an important aspect of healthcare systems, the SMBG device and supplies market will continue to grow. The advances in technology, especially the available kinds of continuous glucose monitors, give market expansion way to more convenient and accurate blood sugar tracking. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

The Diabetes Care Devices Market in Latin America is projected to grow steadily from 2025 to 2033, with a CAGR of 5.64%. The market size is valued at XX million in 2025 and is expected to reach XX million by 2033. The growth is driven by factors such as the rising prevalence of diabetes, increasing awareness about diabetes management, technological advancements in devices, and government initiatives to improve diabetes care. Key market trends include the growing adoption of continuous glucose monitoring devices, the integration of artificial intelligence and data analytics into devices, and the increasing popularity of telehealth services for diabetes management. However, challenges such as the high cost of devices, limited access to healthcare in rural areas, and reimbursement issues may hinder market growth. The market is dominated by companies such as Abbott Diabetes Care, Medtronic, Dexcom, and Roche Diabetes Care, among others. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., October 2022: Becton, Dickinson, and Company and Biocorp announced that they had signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology-a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.. Key drivers for this market are: Increasing Demand for Better Dentistry and Better Aesthetic outcomes, Increase in the Disposable Income. Potential restraints include: High Cost Associated with the Digital Dentistry. Notable trends are: The Continuous Glucose Monitoring Segment is expected to witness the highest growth rate over the forecast period.

Background: Type 2 diabetes rates in the general population have risen with the growing obesity epidemic. Knowledge of temporal patterns and factors associated with comorbid diabetes among stroke patients may enable health practitioners and policy makers to develop interventions aimed at reducing diabetes rates, which may consequently lead to declines in stroke incidence and improvements in stroke outcomes. Methods: Using the Nationwide Inpatient Sample (NIS), a nationally representative data set of US hospital admissions, we assessed trends in the proportion of acute ischemic stroke (AIS) patients with comorbid diabetes from 1997 to 2006. Independent factors associated with comorbid diabetes were evaluated using multivariable logistic regression. Results: Over the study period, the absolute number of AIS hospitalizations declined by 17% (from 489,766 in 1997 to 408,378 in 2006); however, the absolute number of AIS hospitalizations with comorbid type 2 diabetes rose by 27% [from 97,577 (20%) in 1997 to 124,244 (30%) in 2006, p < 0.001]. The rise in comorbid diabetes over time was more pronounced in patients who were relatively younger, Black or ‘other’ race, on Medicaid, or admitted to hospitals located in the South. Factors independently associated with higher odds of diabetes in AIS patients were Black or ‘other’ versus White race, congestive heart failure, peripheral vascular disease, history of myocardial infarction, renal disease and hypertension. Conclusions: Although hospitalizations for AIS in the US decreased from 1997 to 2006, there was a steep rise in the proportion with comorbid diabetes (from 1 in 5 to almost 1 in 3). Specific patient populations may be potential targets for mitigating this trend.

The Colorado Department of Public Health and Environment has developed community level estimates for the number of adults ever diagnosed with Diabetes (excluding gestational, borderline, or pre-diabetes) for each census tract in Colorado based on modeled survey data collected in the Colorado Behavioral Risk Factor Surveillance System and population, race, gender, and age estimates for each census tract from the American Community Survey. For additional information pertaining to the data and methodology, please visit the CDPHE Community Level Estimates home page.The estimate for each census tract represents an average that was derived using multiple years of BRFSS survey responses (2013-2016) and American Community Survey population & demographic estimates.CDPHE used a model-based approach to measure the relationship between age, race, gender, poverty, education, location and existing Diabetes data from the Colorado BRFSS survey, and applied this relationship to predict the number of persons' who have Diabetes for each census tract in Colorado. These probabilities are based on demographic stratification to American Community Survey population estimates (2011-2015) for each census tract in Colorado. The model ultimately determines (or predicts) an estimate representing the percentage of adults who have Diabetes for each census tract in Colorado. These estimates do not represent direct survey estimates.

Summary statistics for individual-level and network-level variables.

Causal mediation of PRS with carbohydrate and protein intake with type 2 diabetes.